SlideShare ist ein Scribd-Unternehmen logo
1 von 63
Downloaden Sie, um offline zu lesen
Presenter: Dr.Kalaiyarasan
Moderator: Dr.Ritu Singhal
15-Dec-2015
Topics
• Introduction – MDR/XDR global & Indian scenario
• Importance of detecting DR-TB
• Why Xpert MTB/RIF & LPA?
• LPA-Method, advantages, disadvantages, evidence
base, newer developments
• Xpert MTB/RIF-Method, advantages, disadvantages,
evidence base , newer developments
• Conclusion
Introduction
• Drug-resistant TB poses a major threat to control of TB
worldwide.
• Among notified pulmonary TB patients in 2014, an estimated
300 000 (range: 220 000–370 000) had MDR-TB.
• Globally in 2014, 123 000 patients with MDR -TB
or rifampicin resistant tuberculosis (RR-TB) were
notified.
MDR TB
• Globally, 3.3% of new cases (95% CI: 2.2–4.4%) and 20% of
previously treated cases (95%CI: 14–27%) have MDR-TB.
• In India (2014), an estimated 2.2% of new cases (95% CI: 1.9–
2.6%) and 15% of previously treated cases (95%CI: 11–19%)
have MDR-TB.
WHO Global tuberculosis report 2015
WHO Global tuberculosis report 2015
WHO Global tuberculosis report 2015
XDR TB
• Extensively drug-resistant TB (XDR-TB) has been reported by
105 countries.1
• On average, an estimated 9.7% of people with MDR-TB have
XDR-TB (95% CI: 7.4–12%).1
• Sub-national drug resistance surveys (2005-09) showed
4-7% XDR & 21-24% Ofx resistance in MDR isolates.
1. WHO Global tuberculosis report 2015
WHO Global tuberculosis report 2015
Importance of detecting
drug resistant TB
• Earlier treatment initiation
• Improved patient outcomes
• Reducing transmission
• Reducing the emergence MDR-TB and XDR-TB
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
Drug-susceptibility testing
• Phenotypic methods involve culturing M.tuberculosis
in the presence of anti-TB agents to detect growth or
inhibition of growth.
• Genotypic methods target specific molecular
mutations associated with resistance against
individual anti-TB agents.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Advantages of Culture methods
• Bacterial growth can be identified visually or by automated
detection of its metabolism.
• Provides a definitive diagnosis of TB.
• Significantly increases the number of cases identified (30–
50%) when compared with microscopy.
• Provides the necessary isolates for conventional DST.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Disadvantages of culture methods
• More complex and expensive.
• Takes longer time.
• Needs appropriate lab infrastructure & bio-safety
precautions.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Advantages of molecular
methods
• May be applied directly on clinical specimens.
• Can also be used on specimens not suitable for growth-based
assays.
• Simplification and reduction of bio-safety requirements for both
laboratory testing and specimen transport.
• Large number of specimens can be processed at the same time.
Advantages of molecular
methods contd.
• Automation provides standardization & quality assurance of
testing.
• Able to detect mutations associated with lower levels of
phenotypic resistance.
• Detection of specific mutations allows to predict drug resistance
to an entire family of drugs (eg: Aminoglycosides)1.
1. Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to
Amikacin, Kanamycin and Capreomycin: A Systematic Review - Sophia B. Georghiou
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0033275
Why Genexpert/LPA?
Phenotypic DST
• Solid LJ media (around 84 days)
• Liquid Culture (MGIT) (around 42 days)
Molecular DST
• LPA (around 72 hours)
• CB-NAAT (around 2 hours)
PMDT guidelines May 2012
Polymerase chain reaction
(PCR)
• Amplifies a single copy or a few copies of a piece of DNA,
generating thousands to millions of copies of a particular DNA
sequence.
• Denaturation (DNA melting): Two strands of the DNA double helix
are physically separated at a high temperature.
• Annealing step: Temperature is lowered and the two DNA strands
become templates for DNA polymerase to selectively amplify the
target DNA.
• Extension/elongation step
• Final elongation
• Final hold
Three steps of PCR: Denaturation,
annealing and extension
• Primers are target sequence specific oligonucleotides that
serve as template for the DNA polymerase
• Forward and reverse primers flanking the target sequence
allow both DNA strands to be copied simultaneously in both
directions.
Primers
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
HAINs test: MTB DR plus: Line probe assay
• Based on PCR line probe assay
• Identifies M.tuberculosis and detects
Rif & INH resistance in a day
21
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
Principle of Reverse Hybridization
23
Interpretation
24
Advantages
• Rapid detection of resistance to rifampicin (in less
than 48 hours, alone or in combination with
resistance to isoniazid).
• Up to 48 specimens to be processed simultaneously.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Disadvantages
• Does not eliminate the need for conventional culture and DST.
• Available LPAs are recommended for use only on smear-positive sputum
specimens and isolates of M. tuberculosis.
• Current LPAs cannot replace phenotypic DST for second-line anti-TB
agents.
• LPAs cannot identify resistance to specific second-line injectable agents;
thus, they cannot be used to guide the choice of second-line agents
included in individualized MDR-TB regimens.1
• The sensitivity of LPAs to detect resistance to INH is lower (approximately
85%) than that of culture methods.
1. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs: expert group meeting report.
Geneva, World Health Organization, 2013 (WHO/HTM/TB/2013.01) (available at
http://apps.who.int/iris/bitstream/10665/78099/1/WHO_HTM_TB_2013.01.eng.pdf).
Line Probe Assay
• A systematic review and meta-analysis.
• After the literature searches, 14 comparisons for rifampicin and 15
comparisons for isoniazid were identified in 10 articles that used
GenoType MTBDR assays.
Results
• The pooled sensitivity (98.1%, 95% confidence interval (CI) 95.9–
99.1) and specificity (98.7%, 95% CI 97.3–99.4) estimates for
rifampicin resistance were very high and consistent across all
subgroups, assay versions and specimen types.
• The accuracy for isoniazid was variable, with lower sensitivity
(84.3%, 95% CI 76.6–89.8) and more inconsistent than specificity
(99.5%, 95% CI 97.5–99.9).
• While specificity is excellent for isoniazid, sensitivity estimates
were modest and variable.
Conclusion
• The LPA test provides an early diagnosis of resistance to
isoniazid and rifampicin and is highly sensitive and specific for
an early diagnosis of MDR-TB. Sensitivity for isoniazid is
suboptimal
• Based on these findings, it is concluded that the LPA test is to
be implemented as first line test for diagnosis of drug
resistant TB among sputum smear positive patients in high TB
burden countries
Results:
• Overall concordance of RIF and INH result between Genotype
MTBDR plus and MGIT 960 was found to be 96.6 and 84.7 per
cent, respectively.
• The sensitivity, specificity, positive and negative predictive
values for detection of RIF resistance by Genotype MTBDR
plus was found to be 97.6, 94.4, 97.6 and 94.4 per cent
respectively.
Newer LPA
• In 2009, Hain Lifescience introduced a new LPA, the Genotype
MTBDRsl® test
• For the rapid determination of genetic mutations associated with
resistance to fluoroquinolones, aminoglycosides (kanamycin,
amikacin), cyclic peptides (capreomycin), ethambutol and
streptomycin.
• Allows for testing and reporting results within 48 hours.
• Recommended by WHO to be used as a rule-in test for XDR-TB.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
• Objectives: To assess the diagnostic performance of the
GenoType MTBDRsl LPA for the rapid detection of mutations
conferring resistance to ofloxacin (OFX), amikacin (AMK), and
ethambutol and to determine the impact of implementation
on the turnaround time in a high-throughput diagnostic
laboratory.
• 657 patients smear-positive specimens resistant to isoniazid,
rifampin, or both according to the GenoType MTBDRplus
assay were consecutively tested, using the GenoType
MTBDRsl LPA.
• A total of 516 of 657 patient specimens had valid results for
both tests.
• Implementation of this test significantly reduced the
turnaround time by 93.3% (P < 0.001), calculated from the
date that the specimen was received at the laboratory to
reporting second-line results.
sensitivity (95%CI) specificity (95%CI)
OFX 90.7% (80.1–96.0%) 98.1% (95% CI, 96.3–99.0%)
AMK 100% (91.8–100%) 99.4% (95% CI, 98.2–99.8%)
XDR 92.3% (75.9–97.9%) 99.6% (95% CI, 98.5–99.9%)
Newer LPA in research mode
• In 2011, Nipro Corporation completed development of their
LPA-based NTM+MDRTB Detection Kit 2
• Four strips - NTM/MDR-TB, INH, PZA, and FQ strips.
• The NTM/MDR-TB strip was designed to identify four
Mycobacterium species—M. tuberculosis, M. avium, M.
intracellulare, and M. kansasii—and to detect mutations
associated with RIF and INH resistance in M. tuberculosis.
• The INH, PZA, and FQ strips were designed to detect mutations
associated with INH, PZA, and FQ resistance of M. tuberculosis,
respectively.
RESULTS
• In the sputum specimens, sensitivity and specificity for detecting RIF-, PZA-, and
LVX-resistant isolates were both 100% & for detecting INH-resistant isolates were
75.0% and 92.9%, respectively.
Sensitivity Specificity
Rifampicin 98.9 97.3
INH 90.6 100
PZA 89.7 96
Levofloxacin 93 100
A Japanese multi-center study
conducted at 6 hospitals assessed this
new line probe assay in 554
isolates (316 from MTB) and 163
sputum specimens.
Using microscopy and line-probe assays in conjunction with
drug-susceptibility testing (with solid or liquid media)
to diagnose TB
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
Xpert MTB/RIF
• Automated, cartridge-based nucleic acid amplification test
(NAAT) that uses the multidisease GeneXpert platform.
• Performed directly on sputum, processed sputum sediment
and selected extrapulmonary specimens from adults and
children.
• Capacity to have 1, 2, 4, 16, 48 or 80 independently
functioning modules.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
Rifampicin Resistant Sample
 At least 2 of 5 rpoB probes positive within 2 cycles and amplification control positive=
M. tuberculosis complex
 Failure of proper hybridization of one or more rpoB probes= rifampin resistance
41
Advantages - Xpert MTB/RIF
• Simultaneously detects M. tuberculosis and rifampicin resistance
in less than 2 hours.
• The sensitivity for detecting TB is similar to that of to liquid
culture (sensitivity 88%); the specificity is also high (99%).
• The superior performance of Xpert MTB/RIF in detecting TB over
that of microscopy makes it a particularly useful tool for case-
finding among people living with HIV.
1. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert
MTB/RIF assay for the diagnosis of pulmonary and
extrapulmonary TB in adults and children. Policy update. Geneva, World Health Organization,
2013 (WHO/HTM/TB/2013.16) http://www.who.int/tb/laboratory/xpert_policyupdate/en/
Advantages - Xpert MTB/RIF
• As a tool for detecting rifampicin resistance, Xpert MTB/RIF
has a sensitivity of 95% and specificity of 98% when compared
with phenotypic reference standards.
• Biosafety precautions and the training required are minimal.
• For smear-negative culture-positive TB, the pooled sensitivity
of Xpert MTB/RIF has been found to be 68%.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Disadvantages - Xpert MTB/RIF
• A stable uninterruptable electrical supply is needed.
• The ambient operating temperature of the instrument cannot
exceed 30 °C, cartridges must be stored at less than 28 °C.
• The shelf-life of the cartridges must be monitored to prevent
them from expiring before they are used.
• Security measures must be put in place to prevent the theft of
the accompanying laptop or desktop computer.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Disadvantages - Xpert MTB/RIF
• The modules require annual calibration.
• Does not eliminate the need for conventional microscopy,
culture and DST.
• In patients who are not at risk for drug resistance but tested
positive for Rif resistance, a second Xpert MTB/RIF test should
be performed to control for preanalytical and postanalytical
errors, and to improve the clinician’s confidence in the
diagnosis.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
• Infrequent occurrence of false-positive results may be linked
to the detection by Xpert MTB/RIF of strains that are truly
resistant to rifampicin but for which resistance is not detected
by phenotypic culture-based DST.
• In cases of discordant results obtained from Xpert MTB/RIF Vs
phenotypic DST or LPA, the culture isolate should be referred
to a reference laboratory for DNA sequencing.
• while awaiting the results, a clinical decision should be made
whether to continue the MDR-TB regimen.
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Research & Development
GeneXpert Omni
• At just 9 inches tall (about 23 cm) and weighing just 2.2 pounds
(about 1kg), the GeneXpert Omni will run the same PCR-based
cartridge tests.
• Additionally, the GeneXpert Omni is
battery-operated, wireless and web-enabled,
able to transmit instrument & test information
in real-time.
• WHO expects to evaluate the platform in 2016.
GLOBAL TUBERCULOSIS REPORT 2015
Research & Development
Xpert MTB/RIF Ultra
• The current Xpert MTB/RIF test has a limit of detection (LOD) of
130 cfu/ml.
• New innovations, including a larger DNA reaction chamber in the
cartridge, will bring the LOD down ten-fold, to approximately10
cfu/ml (across all strains) — a level similar to or potentially better
than liquid culture.
• Both GeneXpert Omni & Xpert MTB/RIF Ultra is expected to be
available in the first half of 2016.
Summary of WHO’s 2013 policy
recommendations for using
Xpert MTB/RIF
• Should be used rather than conventional microscopy, culture
and DST as the initial diagnostic test in adults and children
suspected of having MDR-TB or HIV-associated TB.
• May be used rather than conventional microscopy and culture
as the initial diagnostic test in all adults and children
suspected of having TB.
• Should be used in preference to conventional microscopy and
culture as the initial diagnostic test for CSF specimens from
patients suspected of having TB meningitis.
Xpert MTB/RIF implementation manual: technical and operational “how-to”; practical considerations. Geneva: World Health Organization; 2014
(WHO/HTM/TB/2014.1). http://apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf.
• May be used as a follow-on test to microscopy in adults
suspected of having TB who are not at risk of MDR-TB or HIV-
associated TB, especially when further testing of smear-
negative specimens is necessary.
• May be used as a replacement test for usual practice
(including conventional microscopy, culture or histopathology)
for testing specific non respiratory specimens from patients
suspected of having extrapulmonary TB .
Xpert MTB/RIF implementation manual: technical and operational “how-to”; practical considerations. Geneva: World Health Organization; 2014
(WHO/HTM/TB/2014.1). http://apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf.
Using the Xpert MTB/RIF assay as an initial diagnostic test for TB followed by drug
susceptibility testing for second-line anti-TB agents when necessary
WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
• A review commissioned by WHO included all of the evidence
on the use of Xpert MTB/RIF published until the end of
February 2013.
The reviews focused on four specific areas of interest:
• using Xpert MTB/RIF to diagnose pulmonary TB and rifampicin
resistance in adults
• using Xpert MTB/RIF to diagnose extrapulmonary TB in adults
and children
• using Xpert MTB/RIF to diagnose pulmonary TB and rifampicin
resistance in children
• the affordability and cost effectiveness of Xpert MTB/RIF for
diagnosing TB.
WHO Xpert MTB/RIF implementation manual 2014
Pooled Sensitivity Pooled Specificity Studies /
Population
Initial diagnostic test
replacing
smear microscopy
88%
(95% credible
interval [CrI], 84-
92%)
99%
(95% CrI, 98-99%)
22 studies, 9008
participants
add-on test following a
negative smear
microscopy result
68%
(95% CrI, 61-74%)
99%
(95% CrI, 98-99%)
23 studies, 7151
participants
cases of smear-positive,
culture-positive TB
98%
(95% CrI, 97-99%)
- 23 studies,
1952 participants
people living with HIV 79%
(95% CrI, 70-86%)
- 7 studies, 1789
participants
for people without HIV
infection
86%
(95% CrI, 76-92%)
- 7 studies, 1470
participants
to detect rifampicin
resistance in adults
95%
(95% CrI, 90-97%)
98%
(95% CrI, 97-99%)
24 studies, 2414
specimens
WHO Xpert MTB/RIF implementation manual 2014
Using Xpert MTB/RIF to diagnose pulmonary TB & Rif resistance in
adults
Using Xpert MTB/RIF to diagnose
extrapulmonary TB in adults &
children
• A total of 15 published studies and 7 unpublished studies (5922
samples) were included in the review.
WHO Xpert MTB/RIF implementation manual 2014
Pooled sensitivity Studies/Samples
Lymph
node/aspirate
84.9% (95% confidence
interval [CI], 72.1-92.4%)
14 studies, 849 samples
Pleural fluid 43.7% (95% CI, 24.8-
64.7%)
17 studies, 1385
specimen
CSF 79.5% (95% CI, 62.0-
90.2%)
16 studies,
709 specimens
Gastric fluid 83.8% (95%
CI, 65.9-93.2%)
12 studies, 1258
samples
Other tissue
specimens
81.2% (95%
CI, 67.7-89.9%)
12 studies, 699
specimens
Using Xpert MTB/RIF to diagnose
pulmonary TB and rifampicin resistance
in children
• A total of 16 studies (12 published, 4 unpublished) were included
in the review.
• The diagnosis of pulmonary TB was evaluated in 13 studies that
included 2603 participants.
WHO Xpert MTB/RIF implementation manual 2014
Sensitivity Specificity
To detect pulmonary
TB in children
(overall)
Sputum - 66%
(95% CrI, 52-77%
Gastric lavage - 66%
(95% CrI, 51-81%)
98% with
narrow
confidence
interval
against culture
13 studies, 2603
participants
To detect rifampicin
resistance in children
86%
(95%CrI, 53-98%) - -
PMDT guidelines May 2012
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif
Conclusion
• LPAs are currently limited to detecting resistance to
rifampicin and isoniazid and are suitable only on smear
positive Specimens.
• Conventional DST is needed to detect resistance to anti-
TB agents other than rifampicin and isoniazid & to detect
XDR-TB.
Conclusion
• Overall the LPA test is a reliable, rapid and easy to
perform for the simultaneous detection of RMP and INH
resistance in M.tuberculosis
• It is recommend that the LPA should serve as an early
guidance of therapy, which should be followed by a
phenotypic DST confirmation for all suspected MDR-TB
patients.
Conclusion
• Although Xpert MTB/RIF is suitable for use at all levels of the
health system & does not require additional laboratory
equipment, it requires care in handling, a stable and
uninterrupted electrical supply, security against theft, adequate
storage space & bio-safety measures.
• Xpert MTB/RIF does not eliminate the need for capacity for
conventional TB microscopy, culture and DST.
• The Xpert MTB/RIF assay is suitable for diagnosing TB and
detecting RR-TB.
• A negative result accurately excludes the possibility of
rifampicin resistance and no further testing is needed to
confirm the negative results. (NPV>99%)
• Microscopy or culture, or both, remain essential for
monitoring treatment since molecular tests based on
DNA detection have not been shown to be suitable.
• Liquid culture, molecular LPAs and the Xpert MTB/RIF
assay should be phased in to programmes in a way that
ensures that the existing capacity for solid culture and
DST is maintained.
Lpa and Genexpert/CBNAAT/Xpert MTB/Rif

Weitere ähnliche Inhalte

Was ist angesagt?

IGRA / TUBERCULIN SKIN TEST.
IGRA / TUBERCULIN SKIN TEST.IGRA / TUBERCULIN SKIN TEST.
IGRA / TUBERCULIN SKIN TEST.Hiba Ashibany
 
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISANGAN KARMAKAR
 
antitubercular drug susceptibility testing
antitubercular drug susceptibility testingantitubercular drug susceptibility testing
antitubercular drug susceptibility testingMalathi Murugesan
 
Recent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosisRecent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosisNishantTawari
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis Shweta Anand
 
Newer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenNewer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenDr Naveen kumar
 
WHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisWHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisprapulla chandra
 
Recent advances in tuberculosis
Recent advances in tuberculosisRecent advances in tuberculosis
Recent advances in tuberculosisDr Amit Vatkar
 
Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs Gaurav S
 
Newer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detectionNewer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detectionApollo Hospitals
 
Shorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelinesShorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelinesAnkur Gupta
 
Recent advances in diagnosis and treatment of tuberculosis
Recent advances in diagnosis and treatment of tuberculosisRecent advances in diagnosis and treatment of tuberculosis
Recent advances in diagnosis and treatment of tuberculosisAdeyemiKayode2
 
Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15Yahya Noori, Ph.D
 
Lab diagnosis of tb dr mostafa lecture
Lab diagnosis of tb dr mostafa lectureLab diagnosis of tb dr mostafa lecture
Lab diagnosis of tb dr mostafa lectureMostafa Mahmoud
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDr.Lalit Kumar
 
Diagnosis of Tuberculosis
Diagnosis of TuberculosisDiagnosis of Tuberculosis
Diagnosis of TuberculosisRohit Vikas
 

Was ist angesagt? (20)

IGRA / TUBERCULIN SKIN TEST.
IGRA / TUBERCULIN SKIN TEST.IGRA / TUBERCULIN SKIN TEST.
IGRA / TUBERCULIN SKIN TEST.
 
Xpert MTB/RIF Ultra newer technology past to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS Xpert MTB/RIF Ultranewer technologypast to future DIAGNOSIS OF TUBERCULOSIS
Xpert MTB/RIF Ultra newer technology past to future DIAGNOSIS OF TUBERCULOSIS
 
NEW TECHNOLOGIES IN DIAGNOSIS OF TUBERCULOSIS
NEW TECHNOLOGIES IN   DIAGNOSIS OF TUBERCULOSIS NEW TECHNOLOGIES IN   DIAGNOSIS OF TUBERCULOSIS
NEW TECHNOLOGIES IN DIAGNOSIS OF TUBERCULOSIS
 
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSISRECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
RECENT ADVANCES IN DIAGNOSIS OF TUBERCULOSIS
 
Molecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosisMolecular diagnosis in tuberculosis
Molecular diagnosis in tuberculosis
 
antitubercular drug susceptibility testing
antitubercular drug susceptibility testingantitubercular drug susceptibility testing
antitubercular drug susceptibility testing
 
Recent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosisRecent advances in Tuberculosis diagnosis
Recent advances in Tuberculosis diagnosis
 
Newer diagnostic methods for tuberculosis
Newer  diagnostic  methods for tuberculosis  Newer  diagnostic  methods for tuberculosis
Newer diagnostic methods for tuberculosis
 
Newer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in childrenNewer methods in diagnosis of tuberculosis in children
Newer methods in diagnosis of tuberculosis in children
 
WHO recommended tests of tuberculosis
WHO recommended tests of tuberculosisWHO recommended tests of tuberculosis
WHO recommended tests of tuberculosis
 
Recent advances in tuberculosis
Recent advances in tuberculosisRecent advances in tuberculosis
Recent advances in tuberculosis
 
Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs
 
Newer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detectionNewer diagnostic methods in tuberculosis detection
Newer diagnostic methods in tuberculosis detection
 
Shorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelinesShorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelines
 
NTM
NTMNTM
NTM
 
Recent advances in diagnosis and treatment of tuberculosis
Recent advances in diagnosis and treatment of tuberculosisRecent advances in diagnosis and treatment of tuberculosis
Recent advances in diagnosis and treatment of tuberculosis
 
Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15Advanced diagnostics of tuberculosis 21 3-15
Advanced diagnostics of tuberculosis 21 3-15
 
Lab diagnosis of tb dr mostafa lecture
Lab diagnosis of tb dr mostafa lectureLab diagnosis of tb dr mostafa lecture
Lab diagnosis of tb dr mostafa lecture
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
 
Diagnosis of Tuberculosis
Diagnosis of TuberculosisDiagnosis of Tuberculosis
Diagnosis of Tuberculosis
 

Ähnlich wie Lpa and Genexpert/CBNAAT/Xpert MTB/Rif

Molecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptxMolecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptxyogeshtomar32
 
what is new in tuberculosis
what is new in tuberculosiswhat is new in tuberculosis
what is new in tuberculosisPathKind Labs
 
18 march what is new in tuberculosis
18 march what is new in tuberculosis18 march what is new in tuberculosis
18 march what is new in tuberculosisPathKind Labs
 
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxwhat is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxPathKind Labs
 
Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)BBrauer25
 
Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014BBrauer25
 
DeEscalate Trial Journal Club
DeEscalate Trial Journal ClubDeEscalate Trial Journal Club
DeEscalate Trial Journal ClubKiron G
 
Anti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TBAnti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TBNeelaBiradar
 
PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"StopTb Italia
 
Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)Anisha Mohan
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programmeHonorato444
 
Diagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosisDiagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosisbiplave karki
 

Ähnlich wie Lpa and Genexpert/CBNAAT/Xpert MTB/Rif (20)

Molecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptxMolecular assay in tuberculosis.pptx
Molecular assay in tuberculosis.pptx
 
what is new in tuberculosis
what is new in tuberculosiswhat is new in tuberculosis
what is new in tuberculosis
 
18 march what is new in tuberculosis
18 march what is new in tuberculosis18 march what is new in tuberculosis
18 march what is new in tuberculosis
 
Mdr tb seminar
Mdr tb seminarMdr tb seminar
Mdr tb seminar
 
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptxwhat is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
what is new in prevention, diagnosis and treatment of tuberculosis tb short.pptx
 
TB Assays 5 Year review
TB Assays 5 Year reviewTB Assays 5 Year review
TB Assays 5 Year review
 
Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)Antimicrobial stewardship 2014 (1)
Antimicrobial stewardship 2014 (1)
 
Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014Antimicrobial Stewardship 2014
Antimicrobial Stewardship 2014
 
Invest to End TB. Save Lives
Invest to End TB. Save LivesInvest to End TB. Save Lives
Invest to End TB. Save Lives
 
MDR TB ppt.pptx
MDR TB  ppt.pptxMDR TB  ppt.pptx
MDR TB ppt.pptx
 
DeEscalate Trial Journal Club
DeEscalate Trial Journal ClubDeEscalate Trial Journal Club
DeEscalate Trial Journal Club
 
Anti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TBAnti tubercular therapy in Skeletal TB
Anti tubercular therapy in Skeletal TB
 
Mdr tuberculosis updates
Mdr tuberculosis updatesMdr tuberculosis updates
Mdr tuberculosis updates
 
Journal mdr tb outcome
Journal mdr tb outcomeJournal mdr tb outcome
Journal mdr tb outcome
 
biofire presentation.pptx
biofire presentation.pptxbiofire presentation.pptx
biofire presentation.pptx
 
PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"PPT Cirillo " Diagnostic laboratory news"
PPT Cirillo " Diagnostic laboratory news"
 
Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)Programmatic management of drug resistant tuberculosis(pmdt)
Programmatic management of drug resistant tuberculosis(pmdt)
 
HIV Resistance (Journal Club)
HIV Resistance (Journal Club)HIV Resistance (Journal Club)
HIV Resistance (Journal Club)
 
Revised national tuberculosis control programme
Revised national tuberculosis control programmeRevised national tuberculosis control programme
Revised national tuberculosis control programme
 
Diagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosisDiagnostic modalities in tuberculosis
Diagnostic modalities in tuberculosis
 

Kürzlich hochgeladen

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 

Kürzlich hochgeladen (20)

Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 

Lpa and Genexpert/CBNAAT/Xpert MTB/Rif

  • 2. Topics • Introduction – MDR/XDR global & Indian scenario • Importance of detecting DR-TB • Why Xpert MTB/RIF & LPA? • LPA-Method, advantages, disadvantages, evidence base, newer developments • Xpert MTB/RIF-Method, advantages, disadvantages, evidence base , newer developments • Conclusion
  • 3. Introduction • Drug-resistant TB poses a major threat to control of TB worldwide. • Among notified pulmonary TB patients in 2014, an estimated 300 000 (range: 220 000–370 000) had MDR-TB. • Globally in 2014, 123 000 patients with MDR -TB or rifampicin resistant tuberculosis (RR-TB) were notified.
  • 4. MDR TB • Globally, 3.3% of new cases (95% CI: 2.2–4.4%) and 20% of previously treated cases (95%CI: 14–27%) have MDR-TB. • In India (2014), an estimated 2.2% of new cases (95% CI: 1.9– 2.6%) and 15% of previously treated cases (95%CI: 11–19%) have MDR-TB. WHO Global tuberculosis report 2015
  • 7. XDR TB • Extensively drug-resistant TB (XDR-TB) has been reported by 105 countries.1 • On average, an estimated 9.7% of people with MDR-TB have XDR-TB (95% CI: 7.4–12%).1 • Sub-national drug resistance surveys (2005-09) showed 4-7% XDR & 21-24% Ofx resistance in MDR isolates. 1. WHO Global tuberculosis report 2015
  • 9. Importance of detecting drug resistant TB • Earlier treatment initiation • Improved patient outcomes • Reducing transmission • Reducing the emergence MDR-TB and XDR-TB
  • 11. Drug-susceptibility testing • Phenotypic methods involve culturing M.tuberculosis in the presence of anti-TB agents to detect growth or inhibition of growth. • Genotypic methods target specific molecular mutations associated with resistance against individual anti-TB agents. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 12. Advantages of Culture methods • Bacterial growth can be identified visually or by automated detection of its metabolism. • Provides a definitive diagnosis of TB. • Significantly increases the number of cases identified (30– 50%) when compared with microscopy. • Provides the necessary isolates for conventional DST. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 13. Disadvantages of culture methods • More complex and expensive. • Takes longer time. • Needs appropriate lab infrastructure & bio-safety precautions. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 14. Advantages of molecular methods • May be applied directly on clinical specimens. • Can also be used on specimens not suitable for growth-based assays. • Simplification and reduction of bio-safety requirements for both laboratory testing and specimen transport. • Large number of specimens can be processed at the same time.
  • 15. Advantages of molecular methods contd. • Automation provides standardization & quality assurance of testing. • Able to detect mutations associated with lower levels of phenotypic resistance. • Detection of specific mutations allows to predict drug resistance to an entire family of drugs (eg: Aminoglycosides)1. 1. Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review - Sophia B. Georghiou http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0033275
  • 16. Why Genexpert/LPA? Phenotypic DST • Solid LJ media (around 84 days) • Liquid Culture (MGIT) (around 42 days) Molecular DST • LPA (around 72 hours) • CB-NAAT (around 2 hours) PMDT guidelines May 2012
  • 17. Polymerase chain reaction (PCR) • Amplifies a single copy or a few copies of a piece of DNA, generating thousands to millions of copies of a particular DNA sequence. • Denaturation (DNA melting): Two strands of the DNA double helix are physically separated at a high temperature. • Annealing step: Temperature is lowered and the two DNA strands become templates for DNA polymerase to selectively amplify the target DNA. • Extension/elongation step • Final elongation • Final hold
  • 18. Three steps of PCR: Denaturation, annealing and extension
  • 19. • Primers are target sequence specific oligonucleotides that serve as template for the DNA polymerase • Forward and reverse primers flanking the target sequence allow both DNA strands to be copied simultaneously in both directions. Primers
  • 21. HAINs test: MTB DR plus: Line probe assay • Based on PCR line probe assay • Identifies M.tuberculosis and detects Rif & INH resistance in a day 21
  • 23. Principle of Reverse Hybridization 23
  • 25. Advantages • Rapid detection of resistance to rifampicin (in less than 48 hours, alone or in combination with resistance to isoniazid). • Up to 48 specimens to be processed simultaneously. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 26. Disadvantages • Does not eliminate the need for conventional culture and DST. • Available LPAs are recommended for use only on smear-positive sputum specimens and isolates of M. tuberculosis. • Current LPAs cannot replace phenotypic DST for second-line anti-TB agents. • LPAs cannot identify resistance to specific second-line injectable agents; thus, they cannot be used to guide the choice of second-line agents included in individualized MDR-TB regimens.1 • The sensitivity of LPAs to detect resistance to INH is lower (approximately 85%) than that of culture methods. 1. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs: expert group meeting report. Geneva, World Health Organization, 2013 (WHO/HTM/TB/2013.01) (available at http://apps.who.int/iris/bitstream/10665/78099/1/WHO_HTM_TB_2013.01.eng.pdf).
  • 28. • A systematic review and meta-analysis. • After the literature searches, 14 comparisons for rifampicin and 15 comparisons for isoniazid were identified in 10 articles that used GenoType MTBDR assays.
  • 29. Results • The pooled sensitivity (98.1%, 95% confidence interval (CI) 95.9– 99.1) and specificity (98.7%, 95% CI 97.3–99.4) estimates for rifampicin resistance were very high and consistent across all subgroups, assay versions and specimen types. • The accuracy for isoniazid was variable, with lower sensitivity (84.3%, 95% CI 76.6–89.8) and more inconsistent than specificity (99.5%, 95% CI 97.5–99.9). • While specificity is excellent for isoniazid, sensitivity estimates were modest and variable.
  • 30. Conclusion • The LPA test provides an early diagnosis of resistance to isoniazid and rifampicin and is highly sensitive and specific for an early diagnosis of MDR-TB. Sensitivity for isoniazid is suboptimal • Based on these findings, it is concluded that the LPA test is to be implemented as first line test for diagnosis of drug resistant TB among sputum smear positive patients in high TB burden countries
  • 31. Results: • Overall concordance of RIF and INH result between Genotype MTBDR plus and MGIT 960 was found to be 96.6 and 84.7 per cent, respectively. • The sensitivity, specificity, positive and negative predictive values for detection of RIF resistance by Genotype MTBDR plus was found to be 97.6, 94.4, 97.6 and 94.4 per cent respectively.
  • 32. Newer LPA • In 2009, Hain Lifescience introduced a new LPA, the Genotype MTBDRsl® test • For the rapid determination of genetic mutations associated with resistance to fluoroquinolones, aminoglycosides (kanamycin, amikacin), cyclic peptides (capreomycin), ethambutol and streptomycin. • Allows for testing and reporting results within 48 hours. • Recommended by WHO to be used as a rule-in test for XDR-TB. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 33. • Objectives: To assess the diagnostic performance of the GenoType MTBDRsl LPA for the rapid detection of mutations conferring resistance to ofloxacin (OFX), amikacin (AMK), and ethambutol and to determine the impact of implementation on the turnaround time in a high-throughput diagnostic laboratory. • 657 patients smear-positive specimens resistant to isoniazid, rifampin, or both according to the GenoType MTBDRplus assay were consecutively tested, using the GenoType MTBDRsl LPA.
  • 34. • A total of 516 of 657 patient specimens had valid results for both tests. • Implementation of this test significantly reduced the turnaround time by 93.3% (P < 0.001), calculated from the date that the specimen was received at the laboratory to reporting second-line results. sensitivity (95%CI) specificity (95%CI) OFX 90.7% (80.1–96.0%) 98.1% (95% CI, 96.3–99.0%) AMK 100% (91.8–100%) 99.4% (95% CI, 98.2–99.8%) XDR 92.3% (75.9–97.9%) 99.6% (95% CI, 98.5–99.9%)
  • 35. Newer LPA in research mode • In 2011, Nipro Corporation completed development of their LPA-based NTM+MDRTB Detection Kit 2 • Four strips - NTM/MDR-TB, INH, PZA, and FQ strips. • The NTM/MDR-TB strip was designed to identify four Mycobacterium species—M. tuberculosis, M. avium, M. intracellulare, and M. kansasii—and to detect mutations associated with RIF and INH resistance in M. tuberculosis. • The INH, PZA, and FQ strips were designed to detect mutations associated with INH, PZA, and FQ resistance of M. tuberculosis, respectively.
  • 36. RESULTS • In the sputum specimens, sensitivity and specificity for detecting RIF-, PZA-, and LVX-resistant isolates were both 100% & for detecting INH-resistant isolates were 75.0% and 92.9%, respectively. Sensitivity Specificity Rifampicin 98.9 97.3 INH 90.6 100 PZA 89.7 96 Levofloxacin 93 100 A Japanese multi-center study conducted at 6 hospitals assessed this new line probe assay in 554 isolates (316 from MTB) and 163 sputum specimens.
  • 37. Using microscopy and line-probe assays in conjunction with drug-susceptibility testing (with solid or liquid media) to diagnose TB WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 39. Xpert MTB/RIF • Automated, cartridge-based nucleic acid amplification test (NAAT) that uses the multidisease GeneXpert platform. • Performed directly on sputum, processed sputum sediment and selected extrapulmonary specimens from adults and children. • Capacity to have 1, 2, 4, 16, 48 or 80 independently functioning modules. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 41. Rifampicin Resistant Sample  At least 2 of 5 rpoB probes positive within 2 cycles and amplification control positive= M. tuberculosis complex  Failure of proper hybridization of one or more rpoB probes= rifampin resistance 41
  • 42. Advantages - Xpert MTB/RIF • Simultaneously detects M. tuberculosis and rifampicin resistance in less than 2 hours. • The sensitivity for detecting TB is similar to that of to liquid culture (sensitivity 88%); the specificity is also high (99%). • The superior performance of Xpert MTB/RIF in detecting TB over that of microscopy makes it a particularly useful tool for case- finding among people living with HIV. 1. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. Geneva, World Health Organization, 2013 (WHO/HTM/TB/2013.16) http://www.who.int/tb/laboratory/xpert_policyupdate/en/
  • 43. Advantages - Xpert MTB/RIF • As a tool for detecting rifampicin resistance, Xpert MTB/RIF has a sensitivity of 95% and specificity of 98% when compared with phenotypic reference standards. • Biosafety precautions and the training required are minimal. • For smear-negative culture-positive TB, the pooled sensitivity of Xpert MTB/RIF has been found to be 68%. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 44. Disadvantages - Xpert MTB/RIF • A stable uninterruptable electrical supply is needed. • The ambient operating temperature of the instrument cannot exceed 30 °C, cartridges must be stored at less than 28 °C. • The shelf-life of the cartridges must be monitored to prevent them from expiring before they are used. • Security measures must be put in place to prevent the theft of the accompanying laptop or desktop computer. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 45. Disadvantages - Xpert MTB/RIF • The modules require annual calibration. • Does not eliminate the need for conventional microscopy, culture and DST. • In patients who are not at risk for drug resistance but tested positive for Rif resistance, a second Xpert MTB/RIF test should be performed to control for preanalytical and postanalytical errors, and to improve the clinician’s confidence in the diagnosis. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 46. • Infrequent occurrence of false-positive results may be linked to the detection by Xpert MTB/RIF of strains that are truly resistant to rifampicin but for which resistance is not detected by phenotypic culture-based DST. • In cases of discordant results obtained from Xpert MTB/RIF Vs phenotypic DST or LPA, the culture isolate should be referred to a reference laboratory for DNA sequencing. • while awaiting the results, a clinical decision should be made whether to continue the MDR-TB regimen. WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 47. Research & Development GeneXpert Omni • At just 9 inches tall (about 23 cm) and weighing just 2.2 pounds (about 1kg), the GeneXpert Omni will run the same PCR-based cartridge tests. • Additionally, the GeneXpert Omni is battery-operated, wireless and web-enabled, able to transmit instrument & test information in real-time. • WHO expects to evaluate the platform in 2016. GLOBAL TUBERCULOSIS REPORT 2015
  • 48. Research & Development Xpert MTB/RIF Ultra • The current Xpert MTB/RIF test has a limit of detection (LOD) of 130 cfu/ml. • New innovations, including a larger DNA reaction chamber in the cartridge, will bring the LOD down ten-fold, to approximately10 cfu/ml (across all strains) — a level similar to or potentially better than liquid culture. • Both GeneXpert Omni & Xpert MTB/RIF Ultra is expected to be available in the first half of 2016.
  • 49. Summary of WHO’s 2013 policy recommendations for using Xpert MTB/RIF • Should be used rather than conventional microscopy, culture and DST as the initial diagnostic test in adults and children suspected of having MDR-TB or HIV-associated TB. • May be used rather than conventional microscopy and culture as the initial diagnostic test in all adults and children suspected of having TB. • Should be used in preference to conventional microscopy and culture as the initial diagnostic test for CSF specimens from patients suspected of having TB meningitis. Xpert MTB/RIF implementation manual: technical and operational “how-to”; practical considerations. Geneva: World Health Organization; 2014 (WHO/HTM/TB/2014.1). http://apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf.
  • 50. • May be used as a follow-on test to microscopy in adults suspected of having TB who are not at risk of MDR-TB or HIV- associated TB, especially when further testing of smear- negative specimens is necessary. • May be used as a replacement test for usual practice (including conventional microscopy, culture or histopathology) for testing specific non respiratory specimens from patients suspected of having extrapulmonary TB . Xpert MTB/RIF implementation manual: technical and operational “how-to”; practical considerations. Geneva: World Health Organization; 2014 (WHO/HTM/TB/2014.1). http://apps.who.int/iris/bitstream/10665/112469/1/9789241506700_eng.pdf.
  • 51. Using the Xpert MTB/RIF assay as an initial diagnostic test for TB followed by drug susceptibility testing for second-line anti-TB agents when necessary WHO IMPLEMENTING TUBERCULOSIS DIAGNOSTICS Policy framework, April 2015
  • 53. • A review commissioned by WHO included all of the evidence on the use of Xpert MTB/RIF published until the end of February 2013. The reviews focused on four specific areas of interest: • using Xpert MTB/RIF to diagnose pulmonary TB and rifampicin resistance in adults • using Xpert MTB/RIF to diagnose extrapulmonary TB in adults and children • using Xpert MTB/RIF to diagnose pulmonary TB and rifampicin resistance in children • the affordability and cost effectiveness of Xpert MTB/RIF for diagnosing TB. WHO Xpert MTB/RIF implementation manual 2014
  • 54. Pooled Sensitivity Pooled Specificity Studies / Population Initial diagnostic test replacing smear microscopy 88% (95% credible interval [CrI], 84- 92%) 99% (95% CrI, 98-99%) 22 studies, 9008 participants add-on test following a negative smear microscopy result 68% (95% CrI, 61-74%) 99% (95% CrI, 98-99%) 23 studies, 7151 participants cases of smear-positive, culture-positive TB 98% (95% CrI, 97-99%) - 23 studies, 1952 participants people living with HIV 79% (95% CrI, 70-86%) - 7 studies, 1789 participants for people without HIV infection 86% (95% CrI, 76-92%) - 7 studies, 1470 participants to detect rifampicin resistance in adults 95% (95% CrI, 90-97%) 98% (95% CrI, 97-99%) 24 studies, 2414 specimens WHO Xpert MTB/RIF implementation manual 2014 Using Xpert MTB/RIF to diagnose pulmonary TB & Rif resistance in adults
  • 55. Using Xpert MTB/RIF to diagnose extrapulmonary TB in adults & children • A total of 15 published studies and 7 unpublished studies (5922 samples) were included in the review. WHO Xpert MTB/RIF implementation manual 2014 Pooled sensitivity Studies/Samples Lymph node/aspirate 84.9% (95% confidence interval [CI], 72.1-92.4%) 14 studies, 849 samples Pleural fluid 43.7% (95% CI, 24.8- 64.7%) 17 studies, 1385 specimen CSF 79.5% (95% CI, 62.0- 90.2%) 16 studies, 709 specimens Gastric fluid 83.8% (95% CI, 65.9-93.2%) 12 studies, 1258 samples Other tissue specimens 81.2% (95% CI, 67.7-89.9%) 12 studies, 699 specimens
  • 56. Using Xpert MTB/RIF to diagnose pulmonary TB and rifampicin resistance in children • A total of 16 studies (12 published, 4 unpublished) were included in the review. • The diagnosis of pulmonary TB was evaluated in 13 studies that included 2603 participants. WHO Xpert MTB/RIF implementation manual 2014 Sensitivity Specificity To detect pulmonary TB in children (overall) Sputum - 66% (95% CrI, 52-77% Gastric lavage - 66% (95% CrI, 51-81%) 98% with narrow confidence interval against culture 13 studies, 2603 participants To detect rifampicin resistance in children 86% (95%CrI, 53-98%) - -
  • 59. Conclusion • LPAs are currently limited to detecting resistance to rifampicin and isoniazid and are suitable only on smear positive Specimens. • Conventional DST is needed to detect resistance to anti- TB agents other than rifampicin and isoniazid & to detect XDR-TB.
  • 60. Conclusion • Overall the LPA test is a reliable, rapid and easy to perform for the simultaneous detection of RMP and INH resistance in M.tuberculosis • It is recommend that the LPA should serve as an early guidance of therapy, which should be followed by a phenotypic DST confirmation for all suspected MDR-TB patients.
  • 61. Conclusion • Although Xpert MTB/RIF is suitable for use at all levels of the health system & does not require additional laboratory equipment, it requires care in handling, a stable and uninterrupted electrical supply, security against theft, adequate storage space & bio-safety measures. • Xpert MTB/RIF does not eliminate the need for capacity for conventional TB microscopy, culture and DST. • The Xpert MTB/RIF assay is suitable for diagnosing TB and detecting RR-TB. • A negative result accurately excludes the possibility of rifampicin resistance and no further testing is needed to confirm the negative results. (NPV>99%)
  • 62. • Microscopy or culture, or both, remain essential for monitoring treatment since molecular tests based on DNA detection have not been shown to be suitable. • Liquid culture, molecular LPAs and the Xpert MTB/RIF assay should be phased in to programmes in a way that ensures that the existing capacity for solid culture and DST is maintained.

Hinweis der Redaktion

  1. The line-probe assay uses the reverse hybridization technology.c DNA-probes immobilized in parallel lines on a paper strip. The target DNA, previously extracted by boiling, is PCR-amplified using biotinylated primers and finally incubated with the strip. Once the hybridization has been carried out under highly stringent conditions and the unbound amplicons have been washed out, developed following the addition of a streptavidin-labeled enzyme and a colored bans develop on adding chromogenic substrate